Targeted Cancer Therapies A New Hope in the Fight Against Cancer
Cetuximab (Erbitux) targets the epidermal growth factor receptor (EGFR) found overexpressed in several Targeted Cancer Therapies including colorectal, lung, pancreatic and head and neck cancers.
It inhibits downstream signaling and tumor proliferation. Tyrosine kinase inhibitors like Gefitinib (Iressa) and Erlotinib (Tarceva) target the intracellular portion of EGFR.
They block EGFR tyrosine kinase activity and growth-promoting signals in lung cancer with EGFR mutations.
Get More Insights: Targeted Cancer Therapies
(https://medium.com/@avantika.cmi/targeted-cancer-therapies-a-more-precise-approach-to-fighting-cancer-86a6d3367301
)
Cetuximab (Erbitux) targets the epidermal growth factor receptor (EGFR) found overexpressed in several Targeted Cancer Therapies including colorectal, lung, pancreatic and head and neck cancers.
It inhibits downstream signaling and tumor proliferation. Tyrosine kinase inhibitors like Gefitinib (Iressa) and Erlotinib (Tarceva) target the intracellular portion of EGFR.
They block EGFR tyrosine kinase activity and growth-promoting signals in lung cancer with EGFR mutations.
Get More Insights: Targeted Cancer Therapies
(https://medium.com/@avantika.cmi/targeted-cancer-therapies-a-more-precise-approach-to-fighting-cancer-86a6d3367301
)
Targeted Cancer Therapies A New Hope in the Fight Against Cancer
Cetuximab (Erbitux) targets the epidermal growth factor receptor (EGFR) found overexpressed in several Targeted Cancer Therapies including colorectal, lung, pancreatic and head and neck cancers.
It inhibits downstream signaling and tumor proliferation. Tyrosine kinase inhibitors like Gefitinib (Iressa) and Erlotinib (Tarceva) target the intracellular portion of EGFR.
They block EGFR tyrosine kinase activity and growth-promoting signals in lung cancer with EGFR mutations.
Get More Insights: Targeted Cancer Therapies
(https://medium.com/@avantika.cmi/targeted-cancer-therapies-a-more-precise-approach-to-fighting-cancer-86a6d3367301
)
0 Commentarios
0 Acciones